Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.
- Scheme of arrangement approved by NSW Supreme Court
- Trading of Apiam shares suspended from 6 February 2026
- Special dividend ex-date set for 12 February 2026
- Scheme implementation expected on 23 February 2026
- Acquisition led by Adamantem Capital entities
Scheme Approval and Legal Effectiveness
Apiam Animal Health Limited (ASX, AHX) has reached a significant milestone in its proposed acquisition by entities controlled by Adamantem Capital. The Supreme Court of New South Wales has formally approved the scheme of arrangement, making the acquisition legally effective as of 6 February 2026. This approval follows a thorough legal process and confirms the court’s endorsement of the transaction structure.
Trading Suspension and Market Impact
Following the court’s approval, trading of Apiam shares on the Australian Securities Exchange was suspended at the close of trading on 6 February. This suspension is standard practice in such transactions, preventing market volatility and ensuring orderly completion of the scheme. Investors holding Apiam shares will now await further developments as the acquisition progresses toward implementation.
Key Dates and Dividend Details
The company has outlined a timetable of important dates related to the scheme. Notably, the special dividend will go ex-dividend on 12 February 2026, with the record date set for 13 February. Payment of this dividend is scheduled for 16 February. The scheme record date, which determines eligible shareholders for the acquisition, is 18 February, with the final implementation date expected on 23 February 2026. These dates are indicative and subject to change, but they provide a clear roadmap for shareholders.
About Apiam and the Acquisition
Apiam Animal Health is a leading rural veterinary services provider in Australia, operating over 80 clinics and employing more than 1,000 staff nationwide. The acquisition by Adamantem Capital Fund II, managed by Adamantem Capital Management, represents a strategic move to consolidate Apiam’s position in the veterinary sector. The transaction is structured as a scheme of arrangement, a common method for takeovers in Australia, which requires court approval and shareholder agreement.
Looking Ahead
As the scheme moves toward implementation, shareholders and market observers will be closely monitoring any updates from Apiam and Adamantem. The completion of this acquisition could reshape the competitive landscape in Australian veterinary services, with potential implications for service delivery and regional market dynamics.
Bottom Line?
With the scheme now effective and trading suspended, all eyes turn to the upcoming implementation and dividend dates.
Questions in the middle?
- What are the final financial terms and valuation details of the acquisition?
- How will Adamantem Capital’s ownership influence Apiam’s strategic direction?
- Are there any regulatory or operational risks that could delay scheme implementation?